About Us

Genteract’s core technology is a novel unsupervised machine learning methodology for identifying gene-environment interactions (GxEs), which allows us to perform functional interpretation of the human genome at a scale that was not previously possible.  
Understanding GxEs and developing techniques to identify the pieces of the genome responsible for these interactions and to predict any given response based on genomic information is the basis of precision medicine. 
Our vision is a future in which precision medicine is the norm, as a basic standard of care. 

Our Team

Brody Holohan, PhD

Co-Founder, CEO, CSO


Developed Genteract’s novel analysis methodologies. Published seven peer-reviewed papers, identified two new genetic disorders, and repurposed an existing cancer therapy for treatment through a new mechanism. 

Raphael Laderman

Co-Founder, COO


Former President Nio Games,, Former CTO, iSyndicate and others, Former Bio-researcher 

Linda Banks, MS

Lead Data Scientist


MS in Quantitative Biomedical Science from Dartmouth. Applied data science methods to accurately establish biologically and analytically correct predictions of anti-drug antibodies induced by biologic treatments for HIV. 

Matthew Likens

Advisor


 Former CEO, Ulthera

Dr. Jerry W. Shay

Advisor


Distinguished Chair in Geriatrics
UT Southwestern Cell Biology,
Telomeres, Aging and Cancer

Dr. Tim deMeyer

Advisor


University of Ghent, Computational Biology, Genomics 

Ralph Leyga

Dev/Ops


Former lead developer at Scitivate, DealRoom, Fundology

Darina Ivnitskaya

Developer


MS in Computer Science

Bryan Rostata

Developer


BS in Computer Science